Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in pediatric patients with active eosinophilic esophagitis
2019-003078-24Phase 3
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing Dupilumab with Placebo (2 arms). Primary endpoint: Histologic response at primary time point.
02
Drugs
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on 2019-003078-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003078-24.